                         SEQUENCE LISTING

<110>  ADIENNE S.A.
 
<120>  METHODS OF TREATING DERMATOMYOSITIS

<130>  2795.061PC01

<150>  US 63/201,806
<151>  2021-05-13

<160>  16    

<170>  PatentIn version 3.5

<210>  1
<211>  336
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Constant Region Amino Acid Sequence; Anti-CD26 mAb 
       (begelomab)

<400>  1

Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys Gly 
1               5                   10                  15      


Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr 
            20                  25                  30          


Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser 
        35                  40                  45              


Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu Tyr Thr Met 
    50                  55                  60                  


Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr Val 
65                  70                  75                  80  


Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val Asp Lys Lys 
                85                  90                  95      


Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro Cys 
            100                 105                 110         


Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro Ser 
        115                 120                 125             


Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser Leu 
    130                 135                 140                 


Thr Pro Lys Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro 
145                 150                 155                 160 


Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala 
                165                 170                 175     


Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val Val 
            180                 185                 190         


Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe 
        195                 200                 205             


Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg Thr 
    210                 215                 220                 


Ile Ser Lys Ile Lys Gly Leu Val Arg Ala Pro Gln Val Tyr Ile Leu 
225                 230                 235                 240 


Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys Asp Val Ser Leu Thr Cys 
                245                 250                 255     


Leu Val Val Gly Phe Asn Pro Gly Asp Ile Ser Val Glu Trp Thr Ser 
            260                 265                 270         


Asn Gly His Thr Glu Glu Asn Tyr Lys Asp Thr Ala Pro Val Leu Asp 
        275                 280                 285             


Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met Lys Thr Ser 
    290                 295                 300                 


Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg His Glu Gly 
305                 310                 315                 320 


Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser Pro Gly Lys 
                325                 330                 335     


<210>  2
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain Constant Region Amino Acid Sequence; Anti-CD26 mAb 
       (begelomab)

<400>  2

Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu 
1               5                   10                  15      


Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe 
            20                  25                  30          


Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg 
        35                  40                  45              


Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu 
65                  70                  75                  80  


Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser 
                85                  90                  95      


Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys 
            100                 105         


<210>  3
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Variable Region (VH) Amino Acid Sequence; Anti-CD26 
       mAb (begelomab)

<400>  3

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Arg Ser Tyr 
            20                  25                  30          


Asp Ile Asn Trp Val Arg Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Ile Phe Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Trp Thr Val Val Gly Pro Gly Tyr Phe Asp Val Trp Gly Ala 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  4
<211>  360
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Variable Region (VH) Nucleotide Sequence; Anti-CD26 
       mAb (begelomab)

<400>  4
caggtccagc tgcagcagtc tggagctgaa ctggtaaagc ctggggcttc agtgaagttg       60

tcctgcaagg cttctggcta caccttcaga agttatgata taaactgggt gagacagagg      120

cctgaacagg gacttgagtg gattggatgg atttttcctg gagatggtag tactaagtac      180

aatgagaagt tcaagggcaa ggccacactg actacagaca aatcctccag cacagcctac      240

atgcagctca gcaggctgac atctgaggac tctgctgtct atttctgtgc aagatggacg      300

gtagtaggcc cagggtactt cgatgtctgg ggcgcaggga ccacggtcac cgtctcctca      360


<210>  5
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain Variable Region (VL) Amino Acid Sequence; Anti-CD26 
       mAb (begelomab)

<400>  5

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


Asn Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Asn Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  6
<211>  318
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Light Chain Variable Region (VL) Nucleotide Sequence; Anti-CD26 
       mAb (begelomab)

<400>  6
caaattgttc tcacccagtc tccagcaatc atgtctgcat ctccagggga gaaggtcacc       60

ataacctgca gtgccagctc aagtgtaagt tacatgaact ggttccagca gaagccaggc      120

acttctccca aactctggat ttatagcacc tccaacctgg cttctggagt ccctgctcgc      180

ttcagtggca gtggatctgg gacctcttac tctctcacaa tcagccgaat ggaggctgaa      240

gatgctgcca cttattactg ccagcaaagg agtagttacc cgaacacgtt cggagggggg      300

accaagctgg aaataaaa                                                    318


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain CDR1 Amino Acid Sequence; Anti-CD26 mAb (begelomab)

<400>  7

Gly Tyr Thr Phe Arg Ser Tyr Asp Ile Asn 
1               5                   10  


<210>  8
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain CDR2 Amino Acid Sequence; Anti-CD26 mAb (begelomab)

<400>  8

Trp Ile Phe Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe Lys 
1               5                   10                  15      


<210>  9
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain CDR3 Amino Acid Sequence; Anti-CD26 mAb (begelomab)

<400>  9

Trp Thr Val Val Gly Pro Gly Tyr Phe Asp Val 
1               5                   10      


<210>  10
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain CDR1 Amino Acid Sequence; Anti-CD26 mAb (begelomab)

<400>  10

Ser Ala Ser Ser Ser Val Ser Tyr Met Asn 
1               5                   10  


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain CDR2 Amino Acid Sequence; Anti-CD26 mAb (begelomab)

<400>  11

Ser Thr Ser Asn Leu Ala Ser 
1               5           


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain CDR3 Amino Acid Sequence; Anti-CD26 mAb (begelomab)

<400>  12

Gln Gln Arg Ser Ser Tyr Pro Asn Thr 
1               5                   


<210>  13
<211>  1008
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Constant Region Nucleotide Sequence; Anti-CD26 mAb 
       (begelomab)

<400>  13
gccaaaacaa cacccccatc agtctatcca ctggcccctg ggtgtggaga tacaactggt       60

tcctccgtga ctctgggatg cctggtcaag ggctacttcc ctgagtcagt gactgtgact      120

tggaactctg gatccctgtc cagcagtgtg cacaccttcc cagctctcct gcagtctgga      180

ctctacacta tgagcagctc agtgactgtc ccctccagca cctggccaag tcagaccgtc      240

acctgcagcg ttgctcaccc agccagcagc accacggtgg acaaaaaact tgagcccagc      300

gggcccattt caacaatcaa cccctgtcct ccatgcaagg agtgtcacaa atgcccagct      360

cctaacctcg agggtggacc atccgtcttc atcttccctc caaatatcaa ggatgtactc      420

atgatctccc tgacacccaa ggtcacgtgt gtggtggtgg atgtgagcga ggatgaccca      480

gacgtccaga tcagctggtt tgtgaacaac gtggaagtac acacagctca gacacaaacc      540

catagagagg attacaacag tactatccgg gtggtcagca ccctccccat ccagcaccag      600

gactggatga gtggcaagga gttcaaatgc aaggtcaaca acaaagacct cccatcaccc      660

atcgagagaa ccatctcaaa aattaaaggg ctagtcagag ctccacaagt atacatcttg      720

ccgccaccag cagagcagtt gtccaggaaa gatgtcagtc tcacttgcct ggtcgtgggc      780

ttcaaccctg gagacatcag tgtggagtgg accagcaatg ggcatacaga ggagaactac      840

aaggacaccg caccagtcct ggactctgac ggttcttact tcatatatag caagctcaat      900

atgaaaacaa gcaagtggga gaaaacagat tccttctcat gcaacgtgag acacgagggt      960

ctgaaaaatt actacctgaa gaagaccatc tcccggtctc cgggtaaa                  1008


<210>  14
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Light Chain Constant Nucleotide Sequence; Anti-CD26 mAb 
       (begelomab)

<400>  14
cgggctgatg ctgcaccaac tgtatccatc ttcccaccat ccagtgagca gttaacatct       60

ggaggtgcct cagtcgtgtg cttcttgaac aacttctacc ccaaagacat caatgtcaag      120

tggaagattg atggcagtga acgacaaaat ggcgtcctga acagttggac tgatcaggac      180

agcaaagaca gcacctacag catgagcagc accctcacgt tgaccaagga cgagtatgaa      240

cgacataaca gttatacctg tgaggccact cacaagacat caacttcacc cattgtcaag      300

agcttcaaca ggaatgagtg t                                                321


<210>  15
<211>  1368
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Nucleotide Sequence; Anti-CD26 mAb (begelomab-CHO 
       optimized)

<400>  15
caagtgcagc ttcagcagtc cggagccgaa ctcgtgaagc cgggagcttc cgtgaagctg       60

agctgcaagg catcggggta taccttccgc tcctacgaca tcaactgggt cagacagagg      120

cccgaacagg gtctggaatg gattggctgg atcttccctg gcgacggttc caccaagtac      180

aacgagaagt tcaagggcaa agccaccctg accactgaca agtcctcatc gaccgcgtac      240

atgcaattga gccggctgac ctccgaggat agcgccgtgt acttctgtgc ccggtggact      300

gtcgtgggac caggctactt tgatgtctgg ggggccggaa ctaccgtgac ggtgtcatca      360

gccaagacta cccctccgtc cgtgtacccc cttgctccgg gatgtggaga caccaccggc      420

tcgtccgtca ctctgggatg cctcgtgaag ggatacttcc ccgaatccgt caccgtgacc      480

tggaacagcg gaagcctgtc ctcgtccgtg catactttcc ctgccctgct gcaatccggc      540

ctgtacacca tgagctccag cgtgaccgtg ccatcctcga cctggcccag ccagaccgtg      600

acttgctcag tggcgcaccc tgcctcatcc actaccgtgg acaagaagct cgagccctcc      660

ggtccgattt caaccatcaa cccttgccca ccctgcaaag aatgccataa gtgtcccgct      720

ccgaatctag aaggcggccc atccgtcttt atcttccctc ccaacattaa ggacgtgctg      780

atgattagtc tgaccccgaa agtcacttgc gtggtggtgg acgtgtccga agatgaccca      840

gacgtgcaga tctcatggtt cgtgaacaac gtggaggtgc acacggccca gacccagacg      900

caccgggagg actacaactc gactatccgc gtggtgtcca cccttccgat ccaacaccag      960

gattggatgt cggggaagga gttcaagtgc aaggtcaaca acaaggatct cccgtccccc     1020

attgagagga caatctctaa gatcaagggc ctcgtcagag cgcctcaggt ctacatcttg     1080

cctcctcccg ccgaacagtt gagccggaag gatgtgtccc tgacttgtct ggtcgtgggg     1140

ttcaatccgg gagacatctc cgtggagtgg acctcgaacg gacacaccga ggaaaactac     1200

aaggacactg caccggtgct ggattccgac ggctcctatt tcatctactc gaagctgaac     1260

atgaaaacct cgaaatggga aaagactgac agcttcagct gcaacgtgcg ccacgagggt     1320

ctgaagaact actacctgaa aaagaccatt tcacggtccc cggggaaa                  1368


<210>  16
<211>  639
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Light Chain Nucleotide Sequence; Anti-CD26 mAb (begelomab-CHO 
       optimized)

<400>  16
cagatcgtgc ttacccaatc cccggcgatt atgtcagcca gccccggaga aaaggtcacc       60

attacttgct cggcatcctc ctccgtgtcg tacatgaact ggttccagca aaagcccggc      120

actagcccaa agctgtggat ctattccacg tccaacctgg cgtcaggagt gcctgcccgc      180

ttttcgggtt ctggcagcgg gactagctac tccctcacca tctcgagaat ggaagctgag      240

gacgccgcca cctactactg tcagcagcgg tcctcctacc cgaacacctt cgggggaggc      300

accaaactgg agatcaaacg ggctgatgct gcaccaactg tatccatctt cccaccatcc      360

agtgagcagt taacatctgg aggtgcctca gtcgtgtgct tcttgaacaa cttctacccc      420

aaagacatca atgtcaagtg gaagattgat ggcagtgaac gacaaaatgg cgtcctgaac      480

agttggactg atcaggacag caaagacagc acctacagca tgagcagcac cctcacgttg      540

accaaggacg agtatgaacg acataacagc tatacctgtg aggccactca caagacatca      600

acttcaccca tcgtcaagag cttcaacagg aatgagtgt                             639


